1. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC 
Alain Vergnenegre, MD, PhD, Bartomeu Massuti, MD, Filippo de Marinis, MD, Enric Carcereny, MD, Enriqueta Felip, MD, Pascal Do, MD, Jose Miguel Sanchez, MD, Luis Paz-Arez, MD, Christos Chouaid, MD, PhD, Rafael Rosell, MD 
Journal of Thoracic Oncology 
Volume 11, Issue 6, Pages (June 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
One-way analysis of cost differences between the treatment arms in France. The bars in the figure were separated on the horizontal axis at €19,364, which represents the cost difference in France; a movement to the right on the horizontal axis represents greater cost savings in the erlotinib arm, whereas a movement to the left represents smaller cost savings.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Probabilistic sensitivity analysis: 500 simulation iterations from the “France” model with a willingness-to-pay threshold of €90,000. All iterations below the willingness-to-pay threshold are cost-effective. QALY, quality-adjusted life-year.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions